Electrophysiology lab efficiency comparison between cryoballoon and point-by-point radiofrequency ablation: a German sub-analysis of the FREEZE Cohort study.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
09 01 2023
Historique:
received: 02 05 2022
accepted: 16 12 2022
entrez: 9 1 2023
pubmed: 10 1 2023
medline: 12 1 2023
Statut: epublish

Résumé

Pulmonary vein isolation (PVI) is recommended to treat paroxysmal and persistent atrial fibrillation (AF). This analysis aimed to assess the hospital efficiency of single-shot cryoballoon ablation (CBA) and point-by-point radiofrequency ablation (RFA). The discrete event simulation used PVI procedure times from the FREEZE Cohort study to establish the electrophysiology (EP) lab occupancy time. 1000 EP lab days were simulated according to an illustrative German hospital, including 3 PVI cases per day using CBA at one site and RFA at the other. The analysis included 1560 CBA patients and 1344 RFA patients from the FREEZE Cohort. Some baseline patients' characteristics were different between groups (age, AF type, and some concomitant diseases), without being statistically associated to ablation procedure time. Mean procedure time was 122.2 ± 39.4 min for CBA and 160.3 ± 53.5 min for RFA (p < 0.0001). RFA was associated with a more than five-fold increase of cumulative overtime compared to CBA over the simulated period (1285 h with RFA and 253 h with CBA). 70.7% of RFA lab days included overtime versus 25.7% for CBA. CBA was associated with more days with an additional hour at the end of the EP lab shift compared to RFA (47.8% vs 11.5% days with one hour left, respectively). CBA is faster and more predictable than point-by-point RFA, and enables improvements in EP lab efficiency, including: fewer cumulative overtime hours, more days where overtime is avoided and more days with remaining time for the staff or for any EP lab usage. Clinical trial registration NCT01360008 (first registration 25/05/2011).

Sections du résumé

BACKGROUND
Pulmonary vein isolation (PVI) is recommended to treat paroxysmal and persistent atrial fibrillation (AF). This analysis aimed to assess the hospital efficiency of single-shot cryoballoon ablation (CBA) and point-by-point radiofrequency ablation (RFA).
METHODS
The discrete event simulation used PVI procedure times from the FREEZE Cohort study to establish the electrophysiology (EP) lab occupancy time. 1000 EP lab days were simulated according to an illustrative German hospital, including 3 PVI cases per day using CBA at one site and RFA at the other.
RESULTS
The analysis included 1560 CBA patients and 1344 RFA patients from the FREEZE Cohort. Some baseline patients' characteristics were different between groups (age, AF type, and some concomitant diseases), without being statistically associated to ablation procedure time. Mean procedure time was 122.2 ± 39.4 min for CBA and 160.3 ± 53.5 min for RFA (p < 0.0001). RFA was associated with a more than five-fold increase of cumulative overtime compared to CBA over the simulated period (1285 h with RFA and 253 h with CBA). 70.7% of RFA lab days included overtime versus 25.7% for CBA. CBA was associated with more days with an additional hour at the end of the EP lab shift compared to RFA (47.8% vs 11.5% days with one hour left, respectively).
CONCLUSION
CBA is faster and more predictable than point-by-point RFA, and enables improvements in EP lab efficiency, including: fewer cumulative overtime hours, more days where overtime is avoided and more days with remaining time for the staff or for any EP lab usage. Clinical trial registration NCT01360008 (first registration 25/05/2011).

Identifiants

pubmed: 36624380
doi: 10.1186/s12872-022-03015-8
pii: 10.1186/s12872-022-03015-8
pmc: PMC9830778
doi:

Banques de données

ClinicalTrials.gov
['NCT01360008']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8

Investigateurs

L Q Wu (LQ)
A Garcia-Alberola (A)
T Massa (T)
G Sabin (G)
A Franke (A)
J J Souza (JJ)
A Stanley (A)
S G Spitzer (SG)
S Willems (S)
T Dierk (T)
K R J Chun (KRJ)
R Borchard (R)
K H Seidl (KH)
R Zahn (R)
G Groschup (G)
I W P Obel (IWP)
J Brachmann (J)
J H Gerds-Li (JH)
R R Gopal (RR)
J Schrickel (J)
T Lewalter (T)
A Stanley (A)
W Moshage (W)
L Eckardt (L)
W Jung (W)
P Kremer (P)
A Lubinski (A)
B Schumacher (B)
L Lickfett (L)
T Münzel (T)
C Steinwender (C)
M Efremidis (M)
T Deneke (T)
D Q Nguyen (DQ)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373–498.
doi: 10.1093/eurheartj/ehaa612
Kuck K-H, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–45.
doi: 10.1056/NEJMoa1602014 pubmed: 27042964
Hoffmann E, et al. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace. 2019;21(9):1313–24.
doi: 10.1093/europace/euz155 pubmed: 31199860 pmcid: 6735953
Deutscher Herzbericht 2019 [German Heart Report 2019].
Hoffmann E, et al. Design and baseline patient characteristics of the prospective, observational, multicenter and multinational cohort study comparing radiofrequency with cryoablation for pulmonary vein isolation in patients with atrial fibrillation—the Freeze Cohort study. Int J Clin Med. 2014;05(19):1161–72.
doi: 10.4236/ijcm.2014.519149
Monnickendam G, de Asmundis C. Why the distribution matters: Using discrete event simulation to demonstrate the impact of the distribution of procedure times on hospital operating room utilisation and average procedure cost. Oper Res Health Care. 2018;16(20–28):2018.
Klein G, et al. Comparison of ‘anatomically designed’ and ‘point-by-point’ catheter ablations for human atrial fibrillation in terms of procedure timing and costs in German hospitals. Europace. 2015;17(7):1030–7.
doi: 10.1093/europace/euu386 pubmed: 25662987
Iacopino S, et al. A comparison of acute procedural outcomes within four generations of cryoballoon catheters utilized in the real-world multicenter experience of 1STOP. J Cardiovasc Electrophysiol. 2020;31(1):80–8.
doi: 10.1111/jce.14271 pubmed: 31701569
Ravi V, et al. A systematic review and meta-analysis comparing second-generation cryoballoon and contact force radiofrequency ablation for initial ablation of paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2020;31(10):2559–71.
doi: 10.1111/jce.14676 pubmed: 32671920
Mörtsell D, et al. Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace. 2019;21(4):581–9.
doi: 10.1093/europace/euy239 pubmed: 30376055
Kowalski M, et al. Using discrete event simulation to model the economic value of shorter procedure times on EP Lab efficiency in the VALUE PVI study. J Invasive Cardiol. 2016;28(5):176–82.
pubmed: 26984931
Kowalski M, Su WW, Holbrook R, Sale A, Braegelmann KM, Calkins H. Impact of cryoballoon ablation on electrophysiology lab efficiency during the treatment of patients with persistent atrial fibrillation: a sub-analysis of the STOP persistent AF study impact of cryoballoon ablation on electrophysiology lab efficiency duri. J Invasive Cardiol. 2021;33:E522–30.
pubmed: 34224381
OECD/European Observatory on Health Systems and Policies. Germany: Country Health Profile 2019, state of health in the EU. Paris: OECD Publishing; 2019. https://doi.org/10.1787/36e21650-en .
Griffiths P, et al. Nurses’ shift length and overtime working in 12 European countries: the association with perceived quality of care and patient safety. Med Care. 2014;52(11):975–81.
doi: 10.1097/MLR.0000000000000233 pubmed: 25226543 pmcid: 4196798
Chun KRJ, et al. The impact of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation on healthcare utilization and costs: an economic analysis from the FIRE AND ICE trial. J Am Heart Assoc. 2017;6(8):e006043.
doi: 10.1161/JAHA.117.006043 pubmed: 28751544 pmcid: 5586445
Kuck KH, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE and ICE trial. Eur Heart J. 2016;37(38):2858–65.
doi: 10.1093/eurheartj/ehw285 pubmed: 27381589 pmcid: 5070448
Kirchhof P, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16.
doi: 10.1056/NEJMoa2019422 pubmed: 32865375
Andrade JG, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2020;384:305–15.
doi: 10.1056/NEJMoa2029980 pubmed: 33197159
Wazni OM, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2020;384:316–24.
doi: 10.1056/NEJMoa2029554 pubmed: 33197158
Kuniss et al. Catheter cryoablation versus antiarrhythmic drug as first-line therapy of paroxysmal atrial fibrillation (Cryo-FIRST). Presented at the German Cardiac Society conference DGK 2020.

Auteurs

Andreas Metzner (A)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany. a.metzner@uke.de.
Department of Cardiology, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, Gebäude Ost 70, 20246, Hamburg, Germany. a.metzner@uke.de.

Florian Straube (F)

Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Munich, Germany.

Roland R Tilz (RR)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.
Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Schleswig-Holstein, University Heart Centre Luebeck, Lübeck, Germany.

Malte Kuniss (M)

Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany.

Georg Noelker (G)

Herz- Und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.

Juergen Tebbenjohanns (J)

HELIOS Klinikum Hildesheim, Medizinische Klinik I - Kardiologie, Hildesheim, Germany.

Dietrich Andresen (D)

Department of Cardiology Paul Gerhardt Diakonie gAG, Evangelisches Krankenhaus Hubertus, Berlin, Germany.

Heinrich Wieneke (H)

Klinik Für Kardiologie und Angiologie, Contilia Herz- Und Gefäßzentrum, Essen, Germany.

Christoph Stellbrink (C)

Department of Cardiology, Klinikum Bielefeld, Bielefeld, Germany.

Jennifer Franke (J)

CardioVascular Center Frankfurt, Frankfurt, Germany.

Uwe Dorwarth (U)

Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Munich, Germany.

Phuong Lien Carion (PL)

Medtronic International Trading Sàrl, Tolochenaz, Switzerland.

Reece Holbrook (R)

Medtronic, Inc., Mounds View, MN, USA.

Matthias Hochadel (M)

Stiftung Institut Fur Herzinfarktforschung, Ludwigshafen, Germany.

Jochen Senges (J)

Stiftung Institut Fur Herzinfarktforschung, Ludwigshafen, Germany.

Ellen Hoffmann (E)

Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Munich, Germany.

Karl-Heinz Kuck (KH)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH